T1	intervention 0 9	Tamoxifen
T2	eligibility 511 549	premenopausal and postmenopausal women
T3	average-age 550 561	35-70 years
T4	eligibility 569 630	deemed to be at an increased risk of developing breast cancer
T5	control 710 717	placebo
T6	duration 722 729	5 years
T7	outcome-Measure 1040 1121	occurrence of breast cancer (invasive breast cancer and ductal carcinoma in situ)
T8	duration 1427 1469	Between April 14, 1992, and March 30, 2001
T9	No-of-participants 1471 1475	7154
T10	intervention-participants 1659 1663	3579
T11	control-participants 1681 1685	3575
T12	outcome 1758 1772	breast cancers
T14	intervention-participants 1807 1811	3579
T16	control-participants 1861 1865	3575
T17	outcome 1952 1984	risk of developing breast cancer
T19	control-participants 2031 2035	3575
T21	intervention-participants 2080 2084	3579
T22	outcome 2005 2015	years 0-10
T23	outcome 2171 2185	after 10 years
T25	control-participants 2201 2205	3295
T27	intervention-participants 2228 2232	3343
T28	outcome 2322 2372	invasive oestrogen receptor-positive breast cancer
T29	outcome 2416 2440	ductal carcinoma in situ
T30	outcome 2497 2547	invasive oestrogen receptor-negative breast cancer
T13	intervention-value 1793 1796	251
T31	intervention-value 1798 1802	7.0%
T15	control-value 1847 1850	350
T32	control-value 1852 1856	9.8%
T18	control-value 2017 2020	226
T33	control-value 2022 2026	6.3%
T20	intervention-value 2066 2069	163
T34	intervention-value 2071 2075	4.6%
T24	control-value 2187 2190	124
T35	control-value 2192 2196	3.8%
T26	intervention-value 2215 2217	88
T36	intervention-value 2219 2223	2.6%
